Excellent points. Obviously they'd be looking at these results through the experience they've already gained from lab tests and ph1 on late stage tumours. Clearly much work to be done, so your caution is sensible. But let's not forget Epichem and think it's an all or nothing bet on MPL.
Ann: PharmAust Shareholders Update and Roadmap, page-23
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $89.95M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 18.5¢ | $111.6K | 601.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 169572 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 613756 | 10 |
View Market Depth
| Last trade - 15.46pm 30/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |